Searched for
NOVO NORDISK WEGOVY
India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...- CEOs are getting ruthless about worker performanceCorporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...
- Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarityEli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The...
- Hims earnings today: Why Hims & Hers Health stock dropped despite raising revenue forecast - here's what investors need to knowHims stock after Hims & Hers earnings: Hims & Hers Health shares dropped significantly after reporting a surprise first-quarter loss and re...
- Novo rebrands diabetes pill as Ozempic to tap blockbuster nameNovo Nordisk is relaunching a diabetes tablet as Ozempic in the United States. This move aims to boost sales by using the strong brand reco...
- US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...
- Global Markets | European equities log steep weekly losses with no resolution to MidEast conflictEuropean stocks saw a significant weekly drop Friday. Investors are concerned about growth and inflation due to Middle East conflict disrup...
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- Eli Lilly Foundayo weight-loss pill vs Novo Nordisk Wegovy oral obesity treatment tablets: Which medicine is the most prescribed across U.S.?Eli Lilly Foundayo was approved in the U.S. on April 1, with prescriptions accepted immediately on LillyDirect, while shipping started on A...
- Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
- Novo Nordisk signs deal with OpenAI to develop new drugsDanish pharmaceuticals group Novo Nordisk, maker of the popular Ozempic and Wegovy anti-obesity drugs, announced Tuesday a "strategic partn...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Emcure slashes prices of weight management drug Poviztra by up to 55%Emcure Pharmaceuticals is making its weight management drug Poviztra more accessible. The price of the semaglutide injection will be cut by...
- Lilly's weight-loss pill wins US approval, sets up next battle with rival Novo NordiskThe US FDA has approved Eli Lilly's new weight-loss pill, Foundayo. This marks a significant step in the ongoing competition with rival Nov...
- Novo Nordisk price cuts set to shake up India’s GLP-1 market, challenge genericsNovo Nordisk is slashing prices for its diabetes and weight loss drugs Ozempic and Wegovy in India. This move aims to make these treatments...
- Novo Nordisk cuts Ozempic and Wegovy prices by up to 48% as GLP-1 competition intensifies in IndiaNovo Nordisk has significantly slashed prices for Ozempic and Wegovy in India, reducing them by 36% and 48% respectively, to enhance patien...
- Wegovy pill explained: Pricing, doses, and where to get Novo Nordisk's oral GLP-1 weight loss drugWegovy pill: Novo Nordisk is launching the first oral GLP-1 pill for weight loss, offering a more affordable alternative to injections. The...
- Hims stock tanks over 20% after Wegovy deal collapse — why Novo Nordisk’s breakup over weight loss drugs is shaking up Wall StreetHims stock took a major hit after Novo Nordisk suddenly ended their Wegovy partnership, causing shares to drop over 20% in a single day. Th...
- Novo Nordisk's stock rises as Ozempic beat analysts' expectations in salesIn its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage notifications'.
- Biggest pharma blockbuster? All about Wegovy, Novo Nordisk's obesity drug, that cuts risk of heart attacks and strokes by 20%In a groundbreaking achievement, Novo Nordisk's obesity medication Wegovy has not only demonstrated its efficacy in substantial weight loss...
Load More
